PDCD1 and neoplasm: Although an improvement in treatment outcome has been observed in pre-clinical models and early clinical trial results, patients treated with different epigenetic modulating agents have shown increased expression of immune checkpoints such as PD-1/PD-L1 and CTLA-4, which could impair anti-tumor immune responses (101, 121).